Compare Stocks: PHAT, MOR, ATAI, and SUPN

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ATAI Atai Beckley	$7.29 -0.8%	$6.44	$3.27 ▼ $7.45	$2.70B	1.54	6.74 million shs	2.53 million shs
MOR MorphoSys	$18.96	$18.96	$4.18 ▼ $19.50	$2.86B	1.2	1.02 million shs	N/A
PHAT Phathom Pharmaceuticals	$9.18 +2.7%	$10.19	$8.21 ▼ $18.31	$742.67M	0.51	1.36 million shs	894,401 shs
SUPN Supernus Pharmaceuticals	$43.73 -1.0%	$46.81	$42.45 ▼ $59.68	$2.54B	0.56	1.04 million shs	487,775 shs

7 Stocks That Will Be Magnificent in 2026

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ATAI Atai Beckley	0.00%	-1.22%	+1.53%	+60.93%	+59.52%
MOR MorphoSys	0.00%	0.00%	0.00%	0.00%	0.00%
PHAT Phathom Pharmaceuticals	0.00%	+3.49%	+1.66%	-4.28%	-26.21%
SUPN Supernus Pharmaceuticals	0.00%	-4.62%	-4.12%	-5.31%	-2.97%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ATAI Atai Beckley	$7.29 -0.8%	$6.44	$3.27 ▼ $7.45	$2.70B	1.54	6.74 million shs	2.53 million shs
MOR MorphoSys	$18.96	$18.96	$4.18 ▼ $19.50	$2.86B	1.2	1.02 million shs	N/A
PHAT Phathom Pharmaceuticals	$9.18 +2.7%	$10.19	$8.21 ▼ $18.31	$742.67M	0.51	1.36 million shs	894,401 shs
SUPN Supernus Pharmaceuticals	$43.73 -1.0%	$46.81	$42.45 ▼ $59.68	$2.54B	0.56	1.04 million shs	487,775 shs

7 Stocks That Will Be Magnificent in 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ATAI Atai Beckley	0.00%	-1.22%	+1.53%	+60.93%	+59.52%
MOR MorphoSys	0.00%	0.00%	0.00%	0.00%	0.00%
PHAT Phathom Pharmaceuticals	0.00%	+3.49%	+1.66%	-4.28%	-26.21%
SUPN Supernus Pharmaceuticals	0.00%	-4.62%	-4.12%	-5.31%	-2.97%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ATAI Atai Beckley	2.06	Hold	$10.56	44.80% Upside
MOR MorphoSys	0.00	N/A	N/A	N/A
PHAT Phathom Pharmaceuticals	2.88	Moderate Buy	$22.86	148.99% Upside
SUPN Supernus Pharmaceuticals	2.71	Moderate Buy	$62.83	43.68% Upside

Current Analyst Ratings Breakdown

Latest PHAT, MOR, ATAI, and SUPN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/17/2026	ATAI Atai Beckley	Oppenheimer Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Outperform ➝ Market Perform
8/14/2026	PHAT Phathom Pharmaceuticals	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Overweight	$18.00 ➝ $14.00
8/13/2026	ATAI Atai Beckley	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
8/12/2026	ATAI Atai Beckley	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Buy ➝ Hold	$12.00 ➝ $8.00
8/12/2026	ATAI Atai Beckley	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Buy ➝ Hold	$12.00 ➝ $8.00
8/6/2026	SUPN Supernus Pharmaceuticals	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy
7/31/2026	PHAT Phathom Pharmaceuticals	Craig Hallum Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$20.00
7/31/2026	PHAT Phathom Pharmaceuticals	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$25.00 ➝ $22.00
7/31/2026	PHAT Phathom Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$26.00
7/30/2026	PHAT Phathom Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$28.00 ➝ $22.00
7/20/2026	ATAI Atai Beckley	Berenberg Bank Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$7.45

(Data available from 8/30/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ATAI Atai Beckley	$4.09M	661.02	N/A	N/A	$0.69 per share	10.57
MOR MorphoSys	$238.28M	11.99	N/A	N/A	$0.35 per share	54.17
PHAT Phathom Pharmaceuticals	$175.11M	4.24	N/A	N/A	($6.14) per share	-1.50
SUPN Supernus Pharmaceuticals	$718.95M	3.54	$3.78 per share	11.58	$18.52 per share	2.36

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ATAI Atai Beckley	-$660.05M	-$2.18	N/A	N/A	N/A	-14,938.36%	-88.30%	-58.88%	11/12/2026 (Estimated)
MOR MorphoSys	-$205.35M	-$3.48	N/A	N/A	N/A	-226.79%	-694.31%	-22.55%	N/A
PHAT Phathom Pharmaceuticals	-$221.25M	-$1.28	N/A	7.91	N/A	-41.34%	N/A	-20.81%	10/29/2026 (Estimated)
SUPN Supernus Pharmaceuticals	-$38.55M	-$1.92	N/A	11.33	0.81	-13.23%	11.13%	8.10%	11/3/2026 (Estimated)

Latest PHAT, MOR, ATAI, and SUPN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
8/11/2026	Q2 2026	ATAI Atai Beckley	-$0.1075	-$0.09	+$0.0175	-$0.09	$0.60 million	$1.70 million
8/3/2026	Q2 2026 & Merger	SUPN Supernus Pharmaceuticals	$0.4225	-$1.01	-$1.4325	-$1.01	$205.31 million	$219.06 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ATAI Atai Beckley	N/A	N/A	N/A	N/A	N/A
MOR MorphoSys	N/A	N/A	N/A	N/A	N/A
PHAT Phathom Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
SUPN Supernus Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ATAI Atai Beckley	N/A	N/A	N/A
MOR MorphoSys	4.98	1.38	1.38
PHAT Phathom Pharmaceuticals	N/A	1.92	1.87
SUPN Supernus Pharmaceuticals	N/A	2.08	1.84

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ATAI Atai Beckley	28.41%
MOR MorphoSys	18.38%
PHAT Phathom Pharmaceuticals	99.01%
SUPN Supernus Pharmaceuticals	N/A

Insider Ownership

Company	Insider Ownership
ATAI Atai Beckley	19.80%
MOR MorphoSys	0.05%
PHAT Phathom Pharmaceuticals	9.33%
SUPN Supernus Pharmaceuticals	8.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ATAI Atai Beckley	80	370.86 million	297.43 million	Optionable
MOR MorphoSys	730	150.62 million	150.55 million	Not Optionable
PHAT Phathom Pharmaceuticals	110	80.90 million	73.35 million	Optionable
SUPN Supernus Pharmaceuticals	580	58.13 million	53.19 million	Optionable

PHAT, MOR, ATAI, and SUPN Headlines

Recent News About These Companies

156,422 Shares in Supernus Pharmaceuticals, Inc. $SUPN Bought by Man Group plc

August 30 at 5:11 AM | marketbeat.com

SUPN Stock Alert: Halper Sadeh LLC is Investigating Whether Supernus Pharmaceuticals, Inc. is Obtaining a Fair Price for its Shareholders

August 29 at 7:13 AM | businesswire.com

Freestone Grove Partners LP Invests $14.72 Million in Supernus Pharmaceuticals, Inc. $SUPN

August 28 at 4:08 AM | marketbeat.com

91,070 Shares in Supernus Pharmaceuticals, Inc. $SUPN Acquired by Algert Global LLC

August 28 at 3:11 AM | marketbeat.com

25,858 Shares in Supernus Pharmaceuticals, Inc. $SUPN Acquired by PDT Partners LLC

August 27 at 5:21 AM | marketbeat.com

Deutsche Bank AG Takes $2.96 Million Position in Supernus Pharmaceuticals, Inc. $SUPN

August 27 at 3:37 AM | marketbeat.com

Elmind Capital LP Invests $3.26 Billion in Supernus Pharmaceuticals, Inc. $SUPN

August 26, 2026 | marketbeat.com

BlackRock Inc. Purchases New Position in Supernus Pharmaceuticals, Inc. $SUPN

August 26, 2026 | marketbeat.com

ADAR1 Capital Management LLC Makes New $1.29 Million Investment in Supernus Pharmaceuticals, Inc. $SUPN

August 26, 2026 | marketbeat.com

Quantbot Technologies LP Purchases Shares of 47,700 Supernus Pharmaceuticals, Inc. $SUPN

August 25, 2026 | marketbeat.com

Is the Options Market Predicting a Spike in Supernus Pharmaceuticals Stock?

August 24, 2026 | zacks.com

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Receives Consensus Recommendation of "Moderate Buy" from Analysts

August 24, 2026 | marketbeat.com

Supernus Pharmaceuticals Inc

August 22, 2026 | money.usnews.com

NFJ Investment Group LLC Makes New $2.46 Million Investment in Supernus Pharmaceuticals, Inc. $SUPN

August 22, 2026 | marketbeat.com

Great Lakes Advisors LLC Acquires Shares of 29,800 Supernus Pharmaceuticals, Inc. $SUPN

August 22, 2026 | marketbeat.com

Allworth Financial LP Invests $2.36 Million in Supernus Pharmaceuticals, Inc. $SUPN

August 22, 2026 | marketbeat.com

Indivior's Supernus Merger Could Broaden Its Growth Engine in 2026

August 21, 2026 | zacks.com

25,400 Shares in Supernus Pharmaceuticals, Inc. $SUPN Bought by Mystic Asset Management Inc.

August 21, 2026 | marketbeat.com

Rice Hall James & Associates LLC Takes $22.80 Million Position in Supernus Pharmaceuticals, Inc. $SUPN

August 18, 2026 | marketbeat.com

Supernus Pharmaceuticals, Inc. $SUPN Shares Purchased by Bank of America Corp DE

August 15, 2026 | marketbeat.com

Supernus Pharmaceuticals, Inc. $SUPN Shares Sold by Assenagon Asset Management S.A.

August 13, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

PHAT, MOR, ATAI, and SUPN Company Descriptions

Atai Beckley NASDAQ:ATAI

$7.29 -0.06 (-0.82%)

As of 08/28/2026 04:00 PM Eastern

Atai Beckley N.V., a clinical-stage biopharmaceutical company, develops and invests in various therapeutics to treat depression, anxiety, addiction, and other mental health disorders. Its product candidates include COMP360, a proprietary psilocybin which is in Phase 3 program; BPL-003, an intranasal formulation that is in Phase 2a and 2b clinical studies; TRD; VLS-01, an transmucosal film in Phase 1b clinical studies; and ELE-101, a serotonergic psychedelic that is in Phase 1/2a study, for the treatment of treatment resistant depression. The company also develop IBX-210, an intravenous formulation of ibogaine, and DMX-1002, an oral formulation of ibogaine indicated for the treatment of opioid use disorder; EMP-01, an oral formulation of an R-MDMA derivative being developed for the treatment of post-traumatic stress disorder; and EGX-A and EGX-B, psychedelic-like with novel, non-tryptamine structures with differentiated 5-HT receptor pharmacology. In addition, it offers RL-007, an orally bioavailable compound, which is a pro-cognitive neuromodulator for cognitive impairment associated with schizophrenia; and GRX-917, a deuterated etifoxine for the treatment of generalize anxiety disorder. Further, the company develops PCN-101, a subcutaneous formulation of R-ketamine, as a therapy for psychiatric indications initially focused on TRD; KUR-101, a formulation of deuterated mitragynine for the treatment of OUD; and RLS-01, indicated for treatment resistant depression. Atai Beckley N.V. was founded in 2018 and is headquartered in Berlin, Germany with offices in New York and London.

MorphoSys NASDAQ:MOR

$18.96 0.00 (0.00%)

As of 08/28/2026

MorphoSys AG, together with its subsidiaries, engages in the development and commercialization of therapeutics for patients suffering from various cancers in Europe, Asia, and the United States. The company's product pipeline includes Pelabresib that is in Phase 3 trials to treat myelofibrosis and thrombocythemia; Tulmimetostat, a product candidate in Phase 1/2 trials for the treatment of solid tumors and lymphomas; Felzartamab, an antibody directed against CD38 for renal autoimmune diseases and relapsed/refractory multiple myeloma; Ianalumab, a candidate in Phase 3 clinical trials for Sjögren's disease, lupus nephritis, and other autoimmune diseases; Abelacimab that is in Phase 3 trials for venous thromboembolism prevention and cancer-associated thrombosis; Setrusumab, which is in Phase 2/3 trials for osteogenesis imperfecta; and Bimagrumab, a product candidate in Phase 2b trials for adult obesity. It also develops MOR210/TJ210/HIB210 that is in Phase 1 clinical trials for relapsed or refractory advanced solid tumors; and NOV-8, a candidate in Phase 2 trials for the treatment of pulmonary sarcoidosis and dermatitis. The company has collaboration and licensing agreements with I-Mab Biopharma, Novartis, Anthos Therapeutics, Ultragenyx, Mereo BioPharma, Lilly, Human Immunology Biosciences, Inc. Incyte Corporation, and Xencor, Inc. MorphoSys AG was founded in 1992 and is headquartered in Planegg, Germany.

Phathom Pharmaceuticals NASDAQ:PHAT

$9.18 +0.24 (+2.68%)

As of 08/28/2026 04:00 PM Eastern

Phathom Pharmaceuticals, Inc., biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada for an investigational potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. The company was incorporated in 2018 and is headquartered in Florham Park, New Jersey.

Supernus Pharmaceuticals NASDAQ:SUPN

$43.73 -0.46 (-1.04%)

As of 08/28/2026 04:00 PM Eastern

Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age. It also offers comprise Qelbree, a novel non-stimulant indicated for the treatment of attention-deficit hyperactivity disorder (ADHD) in adults and pediatric patients 6 years and older; APOKYN for the acute intermittent treatment of hypomobility or off episodes in patients with advanced Parkinson's Disease (PD); XADAGO for treating levodopa/carbidopa in patients with PD experiencing off episodes; MYOBLOC, a Type B toxin product indicated for the treatment of cervical dystonia and sialorrhea in adults; GOCOVRI for the treatment of dyskinesia in patients with PD; and Osmolex ER for the treatment of Parkinson's disease and drug-induced extrapyramidal reaction in adult patients. In addition, the company's product candidates include SPN-830, a late-stage drug/device combination product candidate for the treatment of off episodes in PD patients; SPN-817, a novel first-in-class selective acetylcholinesterase inhibitor, which is in Phase II clinical trials for the treatment of epilepsy; SPN-820, a product candidate in Phase II clinical trials for treating resistant depression; SPN-443, a preclinical product for the treatment of ADHD/CNS; and SPN-446 for narcolepsy and SPN-448 for the treatment of CNS which is in discovery stage. It markets and sells its products through pharmaceutical wholesalers, specialty pharmacies, and distributors. Supernus Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Rockville, Maryland.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest PHAT, MOR, ATAI, and SUPN Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest PHAT, MOR, ATAI, and SUPN Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

PHAT, MOR, ATAI, and SUPN Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

PHAT, MOR, ATAI, and SUPN Company Descriptions

Atai Beckley NASDAQ:ATAI

MorphoSys NASDAQ:MOR

Phathom Pharmaceuticals NASDAQ:PHAT

Supernus Pharmaceuticals NASDAQ:SUPN

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest PHAT, MOR, ATAI, and SUPN Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest PHAT, MOR, ATAI, and SUPN Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

PHAT, MOR, ATAI, and SUPN Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

PHAT, MOR, ATAI, and SUPN Company Descriptions

Atai Beckley NASDAQ:ATAI

MorphoSys NASDAQ:MOR

Phathom Pharmaceuticals NASDAQ:PHAT

Supernus Pharmaceuticals NASDAQ:SUPN

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools